Purchase this article with an account.
S. Sikder, S.P. Herretes, E. Duh, O. Suwan–Apichon, J.M. G. Reyes, M. Cano, P. Gehlbach, E. Gurewitsch, A. Behrens; Topical Human Amniotic Fluid vs. Potent Antiangiogenesis Protein in the Inhibition of Induced Corneal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1650.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of topical human amniotic fluid (HAF) vs. pigment epithelium–derived factor (PEDF) in arresting corneal neovascularization (CNV).
Hydron pellets containing basic–fibroblast growth factor (bFGF) (Groups I –IV) or bFGF/PEDF (Group V) were implanted in 25 mice using an intrastromal micropocket assay. Topical treatment differed in each group: Group I received saline; II, pre–term HAF; III, term HAF; and IV/V, no treatment. The CNV area (mm2) was evaluated on day 6.
HAF treatment showed a significant decrease in CNV compared to saline (I: 6.38± 0.82; II: 1.03 ± 0.64; III: 1.33 ± 0.74; P < .016). The addition of PEDF to bFGF also demonstrated a reduction in CNV (IV: 8.52 ± 3.91; V: 1.68 ± 1.10; P < .016). Groups II and III were statistically similar and also similar to Group V (P > .421).
Topical HAF appears to be as effective as PEDF in preventing corneal neovascularization.
This PDF is available to Subscribers Only